Array BioPharma, Inc.
🏢 View company profile →329Patents
302Active
329Granted
58Portfolio score
Filing activity: Oct 27, 1998 → Sep 3, 2024 · 87 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7799782B2 | P38 inhibitors and methods of use thereof | Chemistry; Metallurgy | 422 | Active |
| US8933084B2 | Macrocyclic compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 80 | Active |
| US8513263B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 77 | Active |
| US8791123B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 68 | Active |
| US8450322B2 | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 66 | Active |
| US7169926B1 | Dipeptidyl peptidase inhibitors | Chemistry; Metallurgy | 61 | Expired |
| US8324221B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | Chemistry; Metallurgy | 53 | Active |
| US9493476B2 | Macrocyclic compounds as trk kinase inhibitors | Emerging Cross-Sectional Technologies | 43 | Active |
| US8865698B2 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | Emerging Cross-Sectional Technologies | 43 | Active |
| US9127013B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Emerging Cross-Sectional Technologies | 40 | Active |
| US8063050B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | Chemistry; Metallurgy | 36 | Active |
| US7235537B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | Chemistry; Metallurgy | 30 | Expired |
| US8003651B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | Chemistry; Metallurgy | 29 | Active |
| US10208024B2 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | Physics | 27 | Active |
| US9682979B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | Emerging Cross-Sectional Technologies | 25 | Active |
| US10125134B2 | KRas G12C inhibitors | Chemistry; Metallurgy | 25 | Active |
| US9676783B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | Emerging Cross-Sectional Technologies | 22 | Active |
| US7732616B2 | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof | Chemistry; Metallurgy | 22 | Active |
| US8648087B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | Chemistry; Metallurgy | 22 | Active |
| US7449486B2 | Mitotic kinesin inhibitors and methods of use thereof | Chemistry; Metallurgy | 22 | Expired |
| US9718822B2 | Macrocyclic compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 22 | Active |
| US9902741B2 | Macrocyclic compounds as TRK kinase inhibitors | Emerging Cross-Sectional Technologies | 22 | Active |
| US9840519B2 | Macrocyclic compounds as TRK kinase inhibitors | Emerging Cross-Sectional Technologies | 21 | Active |
| US9782414B2 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | Emerging Cross-Sectional Technologies | 21 | Active |
| US6362216B1 | Compounds which inhibit tryptase activity | Chemistry; Metallurgy | 21 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.